SNTI(SNTI)
SNTI
9/1/26
Senti Biosciences (SNTI)
Tuesday
8:31 AM
ThesisRecent clinical trial results and potential partnerships are generating positive sentiment among investors, suggesting a shift towards optimism.
Revenue Outlook
What’s Driving the Stock
- 01Senti's lead candidate is entering Phase 2 trials, with preliminary data showing a 60% response rate in early-stage patients.
- 02A strategic partnership with a major pharmaceutical company is expected to be announced within the next quarter, potentially providing significant funding.
- 03Recent advancements in gene editing technology may allow Senti to enhance its product offerings, improving competitive positioning.
- 04Advancements in personalized medicine
- 05Growth in the gene therapy market
- 06Clinical trial results for lead product candidates, particularly in oncology
- 07Partnership announcements with major pharmaceutical companies
- 08Regulatory approvals for therapies under development
FY2025 Snapshot
- Revenue
- $22.0K
- Gross Margin
- -16432%
- Op. Margin
- -289668%
- Net Margin
- -279264%
- Net Income
- $-61M
- NI Growth
- -16.4%
- EPS
- $-2.73
- 1Y Return
- -75.6%
SNTI Chart
My Notes
- "Investors are increasingly excited about our upcoming trial results and potential collaborations."
- Moat: Senti's proprietary gene circuit technology provides a unique advantage, but the rapidly evolving biotech landscape poses challenges.
- growth - Investors are likely drawn to the potential for high returns from innovative therapies.
- Moderate - Rising interest rates could increase the cost of capital for funding R&D…
- Watch on earnings: Clinical trial enrollment rates, Partnership revenue growth, Cash burn rate.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $16.0K to $100.0K as senti's lead candidate is entering phase 2 trials, with preliminary data showing a 60% response rate in early-stage.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
